Talima Therapeutics
Executives
2Board of Directors
2Talima Therapeutics Management Team
2 Team Members
Talima Therapeutics has 2 executives. Talima Therapeutics's former Chief Executive Officer is Martin Babler.
Name | Work History | Title | Status |
|---|---|---|---|
Martin Babler | Chief Executive Officer | Former | |
Name | Martin Babler | |
|---|---|---|
Work History | ||
Title | Chief Executive Officer | |
Status | Former |
This profile has not been claimed.
Highlight your management team’s expertise.
Talima Therapeutics Board of Directors
2 Board of directors
Talima Therapeutics has 2 board of directors, including Fred Dotzler.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Fred Dotzler | Fred co-founded De Novo in 2000. Prior to De Novo, he was a Managing General Partner of Medicus Venture Partners ("Medicus"), which he founded in 1989. Medicus was an early stage investor in companies such as Anergen, Applied Molecular Evolution, Biosite Diagnostics, Inhale Therapeutic Systems (now Nektar), Omnicell and Tularik. Prior to Medicus, he was a General Partner with Crosspoint Venture Partners for 5 years, where he invested in life sciences companies. Prior to joining Crosspoint, Fred served in executive positions in finance, marketing, sales, manufacturing and business development for companies selling pharmaceuticals (Searle), medical instruments (Merrimack), biotechnology research tools (Millipore), and computers (IBM). Fred earned an MBA from the University of Chicago, a Masters equivalent in Economics from the University of Louvain, Belgium and a BS in Engineering from Iowa State University, where he received a Professional Achievement Citation in Engineering in 2000. He is a member of the Advisory Board of the Journal of Private Equity and a Trustee of the Salk Institute. Fred sits on the boards of Astute Medical , Bayhill Therapeutics , HemaQuest , Talima , SenoRx (NASDAQ: SENO) and Vitreoretinal Technologies . Fred also represented De Novo on investments in Microvention , Renovis , and currently represents De Novo with Oncomed . | Talima Therapeutics | |
James Woody | Talima Therapeutics |
Name | Fred Dotzler | James Woody |
|---|---|---|
Firm | ||
Work History | Fred co-founded De Novo in 2000. Prior to De Novo, he was a Managing General Partner of Medicus Venture Partners ("Medicus"), which he founded in 1989. Medicus was an early stage investor in companies such as Anergen, Applied Molecular Evolution, Biosite Diagnostics, Inhale Therapeutic Systems (now Nektar), Omnicell and Tularik. Prior to Medicus, he was a General Partner with Crosspoint Venture Partners for 5 years, where he invested in life sciences companies. Prior to joining Crosspoint, Fred served in executive positions in finance, marketing, sales, manufacturing and business development for companies selling pharmaceuticals (Searle), medical instruments (Merrimack), biotechnology research tools (Millipore), and computers (IBM). Fred earned an MBA from the University of Chicago, a Masters equivalent in Economics from the University of Louvain, Belgium and a BS in Engineering from Iowa State University, where he received a Professional Achievement Citation in Engineering in 2000. He is a member of the Advisory Board of the Journal of Private Equity and a Trustee of the Salk Institute. Fred sits on the boards of Astute Medical , Bayhill Therapeutics , HemaQuest , Talima , SenoRx (NASDAQ: SENO) and Vitreoretinal Technologies . Fred also represented De Novo on investments in Microvention , Renovis , and currently represents De Novo with Oncomed . | |
Other Seats | Talima Therapeutics | Talima Therapeutics |
Compare Talima Therapeutics to Competitors
EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
Glycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.
Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphere. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphere, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques.
Selective Amplifier Genes offers artificial genes that improve the functions of vectors for use in blood disorders
BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.